BioWorld - Wednesday, January 28, 2026

BioWorld Science

Feb. 22, 2021

View Archived Issues

Positive topline data from pivotal phase III SKYLIGHT 1 and SKYLIGHT 2 studies of fezolinetant

Read More

Insmed reports phase I safety and PK data for treprostinil palmitil inhalation powder

Read More

First-in-human data from SAD and MAD studies of LTI-291 in healthy volunteers

Read More

MMP-14 is a potential marker of vestibular schwannomas

Read More

Valneva initiates further phase III study of chikungunya vaccine candidate VLA-1553

Read More

European Commission approves Heplisav B

Read More

Dosing begins in phase II trial of BBP-418 for limb girdle muscular dystrophy type 2i

Read More

Targeting AMPK-alpha prevents drug-induced hair cell loss and hearing loss

Read More

Study links antidepressant action to TRKB binding

Read More

China NMPA grants conditional approval to toripalimab in nasopharyngeal carcinoma

Read More

Puppet masters of the human gut

Read More

Metabolic changes are antibiotic resistance mechanism

Read More

PTGER4 as new therapeutic target to promote intestinal macrophage healing in IBD

Read More

AUT-00206 ameliorates audition symptoms tied to schizophrenia

Read More

Ascletis reports data on ASC-41 in overweight and obese subjects

Read More

Immunicum reports updated phase II data on ilixadencel in metastatic renal cell carcinoma

Read More

Bionomics reports PK data on new solid dose oral tablet formulation of BNC-210

Read More

Sanofi and GSK study adjuvanted recombinant protein-based COVID-19 vaccine candidate in phase II

Read More

DSMC recommends continuation of phase III study of VB-111 for recurrent ovarian cancer

Read More

MediWound outlines clinical development plans for MWPC-005 in nonmelanoma skin cancer

Read More